Smith & Nephew (ADR) (SNN)
Repairs, regenerates and replaces tissue through orthopaedics, sports medicine and wound care.
Something off on this page? Send us feedback.
Sells joint implants, sports-medicine and ENT tools, and advanced wound-care products through three global business units. Demand spans around 100 countries and depends on hospital procedure volumes, surgeon adoption, reimbursement systems, product innovation and regulated commercial practices.
Builds hip and knee reconstruction systems, trauma products and robotics-assisted surgery through Orthopaedics. Sports Medicine & ENT supplies instruments and repair technologies for soft tissue, while Advanced Wound Management includes dressings and negative-pressure therapy.
Operates through vertical global teams across around 100 countries, with demand and reimbursement conditions distributed beyond its UK base. Its wound-care roots reach back to 1856, while acquisitions helped build arthroscopy, orthopaedic robotics, regenerative repair and shoulder capabilities.
Execution centers on product innovation, procedure-enabling technology and continuous operating improvement across the three units. The business depends on hospital procedure volumes, surgeon adoption, reimbursement systems and regulated physician and distributor relationships.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 11, 2026 | Berenberg Bank | Target | Target: — | Target: $33.88 |
| Sep 2, 2026 | Morgan Stanley | Downgrade | ||
| Aug 31, 2026 | BTIG | Initiate | Rating: — | |
| Aug 6, 2026 | JP Morgan | Downgrade | ||
| Aug 5, 2026 | Barclays | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 27, 2026Cash & short-term investments $754.0M · Total debt $3.79B · Total assets $11.01B · Shareholders' equity $5.18B
- Revenue
- $3.10B
- Operating income
- $448.0M
- Net income
- $303.0M
HistoryDividendAnnual yieldUpcoming
| Institutions | 8.35% | 36.63M ADS | |
|---|---|---|---|
| 295 holders · as of Jun 30, 2026 | |||
| Other | 91.65% | 402.24M ADS | |
| remainder | |||
438.86M ADS (1 ADS = 2 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Cevian Capital II GP LimitedInstitution | 13.58% | 59.59M | filed Jul 27, 2026 |
River Road Asset Management, LLCInstitution | 0.73% | 3.22M ADS | as of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 0.70% | 3.07M ADS | as of Jun 30, 2026 |
Brandes Investment Partners, LPInstitution | 0.49% | 2.15M ADS | as of Jun 30, 2026 |
Dimensional Fund Advisors LPInstitution | 0.42% | 1.84M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Stryker
Broad rival in joint reconstruction, robotics, sports medicine, and ENT
- Zimmer Biomet
Direct rival in hip and knee implants, robotics, and sports medicine
- Johnson & Johnson
DePuy Synthes contests reconstruction, trauma, and sports medicine
- Solventum
Major wound-care rival in negative-pressure therapy and dressings
- CONMED
Focused rival in arthroscopy and sports-medicine soft-tissue repair
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Smith & Nephew (ADR) | $27.52 | −0.63% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| Stryker | $276.35 | +0.79% | $105.11B | 28.4 | 17.3 | 4.1 | +9.4% |
| Zimmer Biomet | $94.63 | +0.33% | $18.25B | 22.9 | 10.8 | 2.1 | +4.8% |
| Johnson & Johnson | $267.81 | −0.62% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Solventum | $89.20 | +0.41% | $15.38B | 10.8 | 13.1 | 1.9 | +2.2% |
| CONMED | $45.46 | +1.72% | $1.34B | 24.1 | 10.1 | 1.0 | +0.3% |
| Median | 24.1 | 13.1 | 2.1 | +4.8% |